Feb. 08, 2025
RESEARCH TRIANGLE PARK, N.C. — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, has announced that Norgine Pharmaceuticals Ltd., a European specialist pharmaceutical company, has commercially launched PEDMARQSI® (sodium thiosulfate injection) in Germany. Licensing Agreement and Market Expansion In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia,